2024年6月1日 · Both mesenchymal (MSC), and hematopoietic stem cells (HSC) can improve the disease activity, and severity in systemic lupus erythematous (SLE). Treatment with MSC, and HSC results in an improvement in the skewed immunological parameters …

3 天之前 · 图9：下调IDO1表达会影响Rapa-SLE-EVs对SLE-B细胞的抑制效果. 该研究首次提出“自噬激活+炎症微环境调控”的双重策略，优化MSC-EVs的免疫调节功能。Rapa-SLE-EVs通过高表达IDO1靶向抑制病理性B细胞，为改进MSC-EVs在治疗包括SLE在内的免疫相关疾病中的应用提供了 …

2024年5月8日 · The therapeutic application of mesenchymal stem cells (MSCs) has good potential as a treatment strategy for systemic lupus erythematosus (SLE), but traditional MSC therapy still has limitations in effectively modulating immune cells.

系统性红斑狼疮（SLE）是一种异质性慢性自身免疫性疾病，目前国际上认可的传统一线治疗方案为糖皮质激素联合环磷酰胺或霉酚酸酯治疗，当然，生物靶向也是一种治疗方向。 但这些治疗方法也只是改善临床症状，降低病死率，对 难治性SLE 依然束手无策。 人体的免疫细胞都是由干细胞发育及分化而来。 近年来，越来越多对干细胞治疗SLE的研究探索在不断深入，其移植后的适应症也逐步增多。 本文就造血干细胞（HSC）和 间充质干细胞 （MSC）移植在难治性狼疮患者中 …

2023年8月3日 · 根据研究报道，MSC治疗SLE的主要作用机制可能包括： 1）调节固有免疫细胞：固有免疫失调与SLE密切相关。 MSC可以抑制DC的成熟和功能，诱导调节性DC产生；抑制TNF-α分泌，并上调IL-10分泌。 另外，巨噬细胞吞噬能力缺陷、异常活化和极化失调与SLE密切相关，MSC通过调节巨噬细胞极化，增强其吞噬活性来发挥免疫调节作用。 2）对B细胞的调控：SLE患者的B细胞免疫耐受异常，产生多种自身抗体；调节性B细胞（Breg）数量减少，免 …

2024年10月1日 · Mesenchymal stem cells (MSCs), which are non-hematopoietic stem cells with multipotent differentiation potential, due to their immunomodulatory, tissue repair, low immunogenicity, and chemotactic properties, have garnered increasing interest in SLE treatment. Studies increasingly reveal the heterogeneous nature of MSC populations.

2019年6月7日 · Allogeneic mesenchymal stem cells (MSCs) exhibit immunoregulatory function in human autoimmune diseases such as systemic lupus erythematosus (SLE), but the...

2021年8月16日 · Mesenchymal stem cells (MSCs) are considered a good source for autoimmune disease and hematological disease therapy. This review will summarize the efficacy, safety, and mechanisms of MSC therapy for SLE. MSC therapy can reduce anti-dsDNA, antinuclear antigen (ANA), proteinuria, and serum creatinine in SLE patients.

2018年12月18日 · Large scale and high-quality randomized controlled trials are required to validate the efficacy and safety of MSC treatment in SLE patients. Current evidences showed that MSC could improve the disease activity, proteinuria and hypocomplementemia in SLE patients.

2021年9月30日 · Recently, mesenchymal stem cell (MSC) therapy for autoimmune diseases, particularly SLE, has gained increasing attention. This therapy can improve the signs and symptoms of refractory SLE by promoting the proliferation of Th2 and Treg cells and inhibiting the activity of Th1, Th17, and B cells, etc.